

### AMENDMENTS TO THE CLAIMS

1-117. (Canceled)

118. (New) A method of processing a cell population that comprises adipose-derived stem cells for reintroduction into a patient, comprising:

removing adipose tissue that comprises adipose-derived stem cells from a patient;

introducing the removed adipose tissue that comprises adipose-derived stem cells into a self-contained cell processing unit configured to maintain a closed pathway;

separating a cell population that comprises adipose-derived stem cells from mature adipocytes and connective tissue present in the adipose tissue that was removed from said patient such that said mature adipocytes and said connective tissue are substantially separated from said cell population that comprises adipose-derived stem cells within said self-contained cell processing unit while maintaining said closed pathway;

concentrating said cell population that comprises adipose-derived stem cells within said self-contained cell processing unit while maintaining said closed pathway;

providing said patient or said concentrated cell population that comprises adipose-derived stem cells an additive; and

reintroducing said concentrated cell population that comprises adipose-derived stem cells into said patient.

119. (New) The method of Claim 118, wherein said concentrated cell population that comprises adipose derived stem cells is reintroduced into said patient while maintaining a closed pathway.

120. (New) The method of Claim 118, wherein said adipose tissue that is removed from said patient is lipoaspirate.

121. (New) The method of Claim 118, wherein said adipose tissue that is removed from said patient is obtained by excisional lipectomy.

122. (New) The method of Claim 118, wherein said concentrated cell population comprising adipose-derived stem cells is reintroduced into said patient subcutaneously, intravenously, intramuscularly, or intraperitoneally.

123. (New) The method of Claim 118, further comprising a disaggregation step, wherein said cell population comprising adipose-derived stem cells contained in the removed adipose tissue is mechanically or enzymatically disaggregated from said mature adipocytes and connective tissue present in the adipose tissue that was removed from said patient prior to separation.

124. (New) The method of Claim 118, wherein said cell population comprising said adipose-derived stem cells is separated from said mature adipocytes and connective tissue present in the adipose tissue that was removed from said patient by employing a filter.

125. (New) The method of Claim 124, wherein said filter is a spinning membrane filter.

126. (New) The method of Claim 124, wherein said filter comprises an antibody.

127. (New) The method of Claim 126, wherein said antibody is selected from the group consisting of AP2, CD3, CD19, and CD11b.

128. (New) The method of Claim 118, wherein said cell population comprising said adipose-derived stem cells is separated from said mature adipocytes and connective tissue present in the adipose tissue that was removed from said patient by centrifugation.

129. (New) The method of Claim 123, wherein said disaggregation step comprises an enzymatic digestion.

130. (New) The method of Claim 129, wherein said enzymatic digestion comprises a collagenase.

131. (New) The method of Claim 129, wherein said enzymatic digestion comprises a neutral protease.

132. (New) The method of Claim 129, wherein said enzymatic digestion comprises trypsin.

133. (New) The method of Claim 118, wherein said adipose-derived stem cells in said concentrated cell population that comprises adipose-derived stem cells are at least 0.1% of the cellular component.

134. (New) The method of Claim 118, wherein said adipose-derived stem cells in said concentrated cell population that comprises adipose-derived stem cells are between about 2% and about 12% of the cellular component.

**Appl. No.** : **10/614,431**  
**Filed** : **July 27, 2003**

135. (New) The method of Claim 118, wherein said concentrated cell population that comprises adipose-derived stem cells has a concentration of about  $2 \times 10^7$  cells/100ml adipose tissue.

136. (New) The method of Claim 118, wherein said concentrated cell population that comprises adipose-derived stem cells comprises endothelial precursor cells.

137. (New) The method of Claim 118, wherein said patient has a disease or injury selected from the group consisting of slow/non-union fractures, osteoporosis, osteogenesis imperfecta, liver failure, hepatitis B, hepatitis C, myocardial infarction, renal disease, retinal disease, ulcers, muscle disorders, cartilage disorder, lung disease, diabetes, intestinal disorder, central nervous system disorder, spinal cord injury, Parkinson's disease, Alzheimer's disease, chronic heart disease, and stroke.

138. (New) The method of Claim 118, wherein said patient has wrinkles, divots, or pockmarks.

139. (New) The method of Claim 118, wherein said patient has liver injury.

140. (New) The method of Claim 139, further comprising measuring liver regeneration.

141. (New) The method of Claim 118, wherein said additive is a tissue or tissue fragment.

142. (New) The method of Claim 118, wherein said additive is demineralized bone.

143. (New) The method of Claim 118, wherein said additive is a compound of the thiaglitazone family.

144. (New) The method of Claim 118, wherein said additive is insulin.

145. (New) The method of Claim 118, wherein said additive is an exogenous DNA.

146. (New) The method of Claim 118, wherein said additive is a biological or artificial scaffold.

147. (New) The method of Claim 146, wherein said biological or artificial scaffold is a resorbable plastic sheath.

148. (New) The method of Claim 118, wherein said additive is an immunosuppressive agent.

**Appl. No.** : **10/614,431**  
**Filed** : **July 27, 2003**

149. (New) The method of Claim 148, wherein said immunosuppressive agent is selected from the group consisting of cyclosporine, myophenylate mofetil, rapamycin, and antithymocyte globulin.

150. (New) The method of Claim 118, wherein said additive is a cell differentiation agent.

151. (New) The method of Claim 150, wherein said cell differentiation agent is a cytokine.

152. (New) The method of Claim 150, wherein said cell differentiation agent is a growth factor.

153. (New) The method of Claim 118, wherein said additive is an antimicrobial agent.

154. (New) The method of Claim 118, wherein said patient is provided said additive.

155. (New) The method of Claim 118, wherein said concentrated cell population that comprises adipose derived stem cells is provided said additive.